{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:08:54Z","timestamp":1789085334793,"version":"build-2803163510"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Diabetic foot ulcers (DFUs) and subsequent amputation incur enormous health and economic burdens to patients, health care systems, and societies. As a novel macrophage-regulating drug, ON101 is a breakthrough treatment for DFUs, which demonstrated significant complete wound healing effects in a phase 3 randomized clinical trial, but its economic value remains unknown.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the cost-effectiveness of an ON101 cream added on to general wound care (GWC; ie, conventional treatments for DFUs, which comprised initial and regular foot examinations, ulcer management, comorbidity control, patient education, and multidisciplinary care) vs GWC alone for DFUs from the Taiwan health care sector perspective.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This economic evaluation used a hypothetical cohort of patients with diabetes, with characteristics mirroring those of the participants in the ON101 trial. A Markov state-transition simulation model was constructed to estimate costs and health outcomes associated with the ON101 with GWC and GWC alone strategies over a 5-year time horizon, discounting costs and effectiveness at 3% annually. Costs were in 2021 US dollars. Data were sourced from the ON101 trial and supplemented from published literature. Deterministic and probabilistic sensitivity analyses were performed to assess the uncertainty of input parameters and study generalizability. The analysis was designed and conducted from September 1, 2020, to January 31, 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>ON101 with GWC vs GWC alone.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>DFU-related complications, costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio.<\/jats:p><\/jats:sec>Results<\/jats:title>Patients in the hypothetical cohort had a mean age of 57 years and an uninfected DFU of 1 to 25 cm2<\/jats:sup> that was present for 4 or more weeks with a Wagner grade of 1 or 2. Over 5 years, the ON101 with GWC group vs the GWC alone group experienced more healing events, stayed for a longer time in the healing state, and had fewer infected DFUs, gangrene, and amputations (eg, 2787 additional healing events and 2766 fewer infected DFU, 72 fewer amputation, and 7 fewer gangrene events in the ON101 with GWC group vs GWC alone group). The ON101 with GWC strategy vs GWC alone yielded an additional 0.038 QALYs at an incremental cost of $571, resulting in $14\u202f922\/QALY gained. Economic results were most sensitive to healing efficacy, drug cost, and health utility of the healing state. Cost-saving results were observed in patient subgroups with poor glycemic control, larger ulcer sizes, longer ulcer durations, and current smoking. The ON101 with GWC strategy was considered cost-effective in 60% to 82% of model iterations against willingness-to-pay thresholds of $32\u202f787\/QALY gained to $98\u202f361\/QALY gained.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this economic evaluation study using a simulated patient cohort, the ON101 with GWC strategy represented good value compared with GWC alone for patients with DFUs from the Taiwan health care sector perspective and may be prioritized for those with high risks for disease progression of DFUs.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.50639","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T16:32:18Z","timestamp":1673541138000},"page":"e2250639","source":"Crossref","is-referenced-by-count":23,"title":["Cost-effectiveness of Novel Macrophage-Regulating Treatment for Wound Healing in Patients With Diabetic Foot Ulcers From the Taiwan Health Care Sector Perspective"],"prefix":"10.1001","volume":"6","author":[{"given":"Hsuan-Yu","family":"Su","sequence":"first","affiliation":[{"name":"Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yi","family":"Yang","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang-Tz","family":"Ou","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan"},{"name":"Department of Pharmacy, College of Medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyi-Gen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Oneness Biotech Co, Ltd, Taipei, Taiwan"},{"name":"Department of Surgery, Tri-Service General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Ching","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Oneness Biotech Co, Ltd, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ju","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Oneness Biotech Co, Ltd, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihchen","family":"Kuo","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan"},{"name":"Division of Metabolism, Endocrinology & Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"issue":"24","key":"zoi221440r1","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1056\/NEJMra1615439","article-title":"Diabetic foot ulcers and their recurrence.","volume":"376","author":"Armstrong","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi221440r2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1080\/07853890.2016.1231932","article-title":"Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis.","volume":"49","author":"Zhang","year":"2017","journal-title":"Ann Med"},{"issue":"8","key":"zoi221440r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2021.107960","article-title":"Patient perspectives on the physical, psycho-social, and financial impacts of diabetic foot ulceration and amputation.","volume":"35","author":"Crocker","year":"2021","journal-title":"J Diabetes Complications"},{"issue":"1","key":"zoi221440r4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/j.semvascsurg.2021.02.006","article-title":"Diabetic foot ulcers: epidemiology and the role of multidisciplinary care teams.","volume":"34","author":"Sorber","year":"2021","journal-title":"Semin Vasc Surg"},{"issue":"3","key":"zoi221440r5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2337\/dc13-2176","article-title":"Burden of diabetic foot ulcers for Medicare and private insurers.","volume":"37","author":"Rice","year":"2014","journal-title":"Diabetes Care"},{"issue":"8","key":"zoi221440r6","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/dme.2019.36.issue-8","article-title":"The cost of diabetic foot ulcers and amputations to the National Health Service in England.","volume":"36","author":"Kerr","year":"2019","journal-title":"Diabet Med"},{"issue":"8","key":"zoi221440r7","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.2337\/dc20-0072","article-title":"Health care costs associated with macrovascular, microvascular, and metabolic complications of type 2 diabetes across time: estimates from a population-based cohort of more than 0.8 million individuals with up to 15 years of follow-up.","volume":"43","author":"Chen","year":"2020","journal-title":"Diabetes Care"},{"key":"zoi221440r8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.diabres.2017.04.013","article-title":"IDF clinical practice recommendation on the diabetic foot: a guide for healthcare professionals.","volume":"127","author":"Ibrahim","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"zoi221440r9","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.v36.S1","article-title":"Practical guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update).","volume":"36","author":"Schaper","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"zoi221440r10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/iwj.12816","article-title":"Diabetic foot ulcer management in clinical practice in the UK: costs and outcomes.","volume":"15","author":"Guest","year":"2018","journal-title":"Int Wound J"},{"issue":"5","key":"zoi221440r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2022.100138","article-title":"Restoring prohealing\/remodeling-associated M2a\/c macrophages using ON101 accelerates diabetic wound healing.","volume":"2","author":"Lin","year":"2022","journal-title":"JID Innov"},{"issue":"9","key":"zoi221440r12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.22607","article-title":"Effect of a novel macrophage-regulating drug on wound healing in patients with diabetic foot ulcers: a randomized clinical trial.","volume":"4","author":"Huang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi221440r13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: a report of the ISPOR CHEERS II Good Practices Task Force.","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"2","key":"zoi221440r14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jfma.2019.02.016","article-title":"Executive summary of the DAROC clinical practice guidelines for diabetes care- 2018.","volume":"119","author":"Diabetes Association of the Republic of China Taiwan","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"zoi221440r15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1046\/j.1524-4733.2000.36027.x","article-title":"The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.","volume":"3","author":"Persson","year":"2000","journal-title":"Value Health"},{"issue":"11","key":"zoi221440r16","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s001250100013","article-title":"Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations.","volume":"44","author":"Ragnarson Tennvall","year":"2001","journal-title":"Diabetologia"},{"issue":"2","key":"zoi221440r17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.12968\/jowc.2008.17.2.28181","article-title":"An economic evaluation of VAC therapy compared with wound dressings in the treatment of diabetic foot ulcers.","volume":"17","author":"Flack","year":"2008","journal-title":"J Wound Care"},{"issue":"4","key":"zoi221440r18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/iwj.2017.14.issue-4","article-title":"A cost-effectiveness analysis of optimal care for diabetic foot ulcers in Australia.","volume":"14","author":"Cheng","year":"2017","journal-title":"Int Wound J"},{"issue":"2","key":"zoi221440r19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/1534734620903239","article-title":"Cost-effectiveness of platelet-rich plasma for diabetic foot ulcer in Spain.","volume":"20","author":"Linertov\u00e1","year":"2021","journal-title":"Int J Low Extrem Wounds"},{"issue":"4","key":"zoi221440r20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/1753-0407.12612","article-title":"Cost-effectiveness of prevention and management of diabetic foot ulcer and amputation in a health resource-limited setting.","volume":"10","author":"Wu","year":"2018","journal-title":"J Diabetes"},{"issue":"6","key":"zoi221440r21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1262-3636(07)70154-4","article-title":"Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments.","volume":"30","author":"Redekop","year":"2004","journal-title":"Diabetes Metab"},{"issue":"9","key":"zoi221440r22","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1111\/jdi.v12.9","article-title":"Valuing health states of people with type 2 diabetes: analyses of the nationwide representative linked databases.","volume":"12","author":"Kuo","year":"2021","journal-title":"J Diabetes Investig"},{"issue":"2","key":"zoi221440r25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches.","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"issue":"3","key":"zoi221440r27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/iwj.v18.3","article-title":"Clinical and economic burden of diabetic foot ulcers: a 5-year longitudinal multi-ethnic cohort study from the tropics.","volume":"18","author":"Lo","year":"2021","journal-title":"Int Wound J"},{"issue":"1","key":"zoi221440r28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/2042018817744513","article-title":"Financial burden of diabetic foot ulcers to world: a progressive topic to discuss always.","volume":"9","author":"Raghav","year":"2018","journal-title":"Ther Adv Endocrinol Metab"},{"key":"zoi221440r29","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.2147\/DMSO.S256243","article-title":"Factors related to severity of diabetic foot ulcer: a systematic review.","volume":"13","author":"Jalilian","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"7","key":"zoi221440r30","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.2337\/dc20-3120","article-title":"Factors associated with healing of diabetes-related foot ulcers: observations from a large prospective real-world cohort.","volume":"44","author":"Zhang","year":"2021","journal-title":"Diabetes Care"},{"issue":"1","key":"zoi221440r31","doi-asserted-by":"publisher","first-page":"18409","DOI":"10.3402\/dfa.v3i0.18409","article-title":"Diabetic foot infections: current concept review.","volume":"3","author":"Hobizal","year":"2012","journal-title":"Diabet Foot Ankle"},{"issue":"2","key":"zoi221440r32","first-page":"59","article-title":"Prognostic factors for lower extremity amputation in diabetic foot ulcer patients.","volume":"9","author":"Kurniawati","year":"2019","journal-title":"J Acute Med"},{"issue":"5","key":"zoi221440r33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124446","article-title":"Diabetic foot complications and their risk factors from a large retrospective cohort study.","volume":"10","author":"Al-Rubeaan","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"zoi221440r34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232395","article-title":"Economic evaluations considering costs and outcomes of diabetic foot ulcer infections: A systematic review.","volume":"15","author":"Woods","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"zoi221440r36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245652","article-title":"Cost-effectiveness of TLC-NOSF dressings versus neutral dressings for the treatment of diabetic foot ulcers in France.","volume":"16","author":"Maunoury","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"zoi221440r37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000795","article-title":"Nationwide trends in the epidemiology of diabetic foot complications and lower-extremity amputation over an 8-year period.","volume":"7","author":"Lin","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"4","key":"zoi221440r38","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","article-title":"AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users.","volume":"34","author":"Vemer","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"zoi221440r39","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1046\/j.1464-5491.2001.00466.x","article-title":"Sodium carboxyl-methyl-cellulose dressings in the management of deep ulcerations of diabetic foot.","volume":"18","author":"Piaggesi","year":"2001","journal-title":"Diabet Med"},{"issue":"1","key":"zoi221440r40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2147\/TCRM","article-title":"Factors affecting therapeutic compliance: a review from the patient\u2019s perspective.","volume":"4","author":"Jin","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"zoi221440r23","unstructured":"National Statistics, ROC (Taiwan). Consumer Price Index. Accessed December 6, 2022. https:\/\/eng.stat.gov.tw\/Point.aspx?sid=t.2&n=4201&sms=11713"},{"key":"zoi221440r24","unstructured":"Center for Drug Evaluation, Taiwan. Guidelines of methodological standards for pharmacoeconomic evaluations. Accessed December 6, 2022. https:\/\/www.cde.org.tw\/HTA\/"},{"key":"zoi221440r26","unstructured":"National Statistics, ROC (Taiwan). National accounts. Accessed December 6, 2022. https:\/\/eng.stat.gov.tw\/cl.aspx?n=2332https:\/\/www.stat.gov.tw\/mp.asp?mp=4"},{"key":"zoi221440r35","unstructured":"US Food and Drug Administration. Highlights of prescribing information. Updated August 2019. Accessed December 6, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/103691s5138lbl.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2800276\/su_2023_oi_221440_1672346541.41337.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T16:32:27Z","timestamp":1673541147000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2800276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.50639","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]}}}